Applied Finance Capital Management LLC Sells 3,138 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Applied Finance Capital Management LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,081 shares of the biopharmaceutical company’s stock after selling 3,138 shares during the period. Applied Finance Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $14,728,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the period. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $31,000. Caitlin John LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth approximately $34,000. FNY Investment Advisers LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $38,000. Finally, Torren Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Down 2.1%

REGN stock opened at $698.25 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The company has a market cap of $73.82 billion, a price-to-earnings ratio of 17.01, a price-to-earnings-growth ratio of 1.58 and a beta of 0.30. The company has a fifty day moving average price of $744.69 and a 200 day moving average price of $744.97. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the previous year, the company posted $8.22 EPS. Regeneron Pharmaceuticals’s revenue was up 19.0% compared to the same quarter last year. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.1 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Royal Bank Of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating for the company in a report on Thursday, April 30th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $826.59.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.